A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02443324 |
Recruitment Status :
Completed
First Posted : May 13, 2015
Last Update Posted : August 18, 2022
|
- Study Details
- Tabular View
- Results Submitted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Gastric Adenocarcinoma Adenocarcinoma of the Gastroesophageal Junction Non-small Cell Lung Cancer Carcinoma, Transitional Cell Biliary Tract Cancer | Drug: Ramucirumab Drug: Pembrolizumab | Phase 1 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 298 participants |
Allocation: | Non-Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | An Open-Label, Multicenter, Phase 1 Study of Ramucirumab Plus Pembrolizumab in Patients With Locally Advanced and Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma, Non-Small Cell Lung Cancer, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer |
Actual Study Start Date : | July 29, 2015 |
Actual Primary Completion Date : | August 31, 2018 |
Actual Study Completion Date : | April 12, 2022 |
Arm | Intervention/treatment |
---|---|
Experimental: Ramucirumab + Pembrolizumab (Phase 1a Schedule 1)
Gastric-GEJ, BTC: Ramucirumab given intravenously (IV) on day 1 and 8 in combination with pembrolizumab given IV on day 1 of a 21 day cycle.
|
Drug: Ramucirumab
Administered IV
Other Names:
Drug: Pembrolizumab Administered IV
Other Name: MK3475 |
Experimental: Ramucirumab + Pembrolizumab (Phase 1a Schedule 2)
Gastric, NSCLC, Urothelial: Ramucirumab given IV on day 1 in combination with pembrolizumab given IV on day 1 of a 21 day cycle.
|
Drug: Ramucirumab
Administered IV
Other Names:
Drug: Pembrolizumab Administered IV
Other Name: MK3475 |
Experimental: Ramucirumab + Pembrolizumab (Phase 1b Cohort A)
Gastric-GEJ: Ramucirumab given IV on day 1 and 8 in combination with pembrolizumab given IV on day 1 of a 21 day cycle.
|
Drug: Ramucirumab
Administered IV
Other Names:
Drug: Pembrolizumab Administered IV
Other Name: MK3475 |
Experimental: Ramucirumab + Pembrolizumab (Phase 1b Cohort A1)
BTC: Ramucirumab given IV on day 1 and 8 in combination with pembrolizumab given IV on day 1 of a 21 day cycle.
|
Drug: Ramucirumab
Administered IV
Other Names:
Drug: Pembrolizumab Administered IV
Other Name: MK3475 |
Experimental: Ramucirumab + Pembrolizumab (Phase 1b Cohort A2)
Gastric-GEJ (first line only): Ramucirumab given IV on day 1 and 8 in combination with pembrolizumab given IV on day 1 of a 21 day cycle.
|
Drug: Ramucirumab
Administered IV
Other Names:
Drug: Pembrolizumab Administered IV
Other Name: MK3475 |
Experimental: Ramucirumab + Pembrolizumab (Phase 1b Cohort B)
Gastric-GEJ: Ramucirumab given IV on day 1 in combination with pembrolizumab given IV on day 1 of a 21 day cycle.
|
Drug: Ramucirumab
Administered IV
Other Names:
Drug: Pembrolizumab Administered IV
Other Name: MK3475 |
Experimental: Ramucirumab + Pembrolizumab (Phase 1b Cohort C)
NSCLC: Ramucirumab given IV on day 1 in combination with pembrolizumab given IV on day 1 of a 21 day cycle.
|
Drug: Ramucirumab
Administered IV
Other Names:
Drug: Pembrolizumab Administered IV
Other Name: MK3475 |
Experimental: Experimental: Ramucirumab + Pembrolizumab (Phase 1b Cohort D)
Urothelial: Ramucirumab given IV on day 1 in combination with pembrolizumab given IV on day 1 of a 21 day cycle.
|
Drug: Ramucirumab
Administered IV
Other Names:
Drug: Pembrolizumab Administered IV
Other Name: MK3475 |
Experimental: Ramucirumab + Pembrolizumab (Phase 1b Cohort E)
NSCLC: Ramucirumab given IV on day 1 in combination with pembrolizumab given IV on day 1 of a 21 day cycle.
|
Drug: Ramucirumab
Administered IV
Other Names:
Drug: Pembrolizumab Administered IV
Other Name: MK3475 |
- Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs) [ Time Frame: Baseline to Measured Progressive Disease (Estimated up to 24 Months) ]
- Proportion of Participants Who Achieve Best Overall Response of Complete Response (CR) or Partial Response (PR) [Objective Response Rate (ORR)] [ Time Frame: Baseline to Measured Progressive Disease (Estimated up 24 Months) ]
- Proportion of Participants who Exhibit Stable Disease (SD) or CR or PR [Disease Control Rate (DCR)] [ Time Frame: Baseline to Measured Progressive Disease (Estimated up 24 Months) ]
- Duration of Response (DoR) [ Time Frame: Date of CR or PR to Date of Objective Disease Progression or Death Due to Any Cause (Estimated up 24 Months) ]
- Time to First Response (TTR) [ Time Frame: Baseline to Date of CR or PR (Estimated up 24 Months) ]
- Progression Free Survival (PFS) [ Time Frame: Baseline to Progressive Disease or Death of Any Cause (Estimated up 24 Months) ]
- Overall Survival (OS) [ Time Frame: Baseline to Death from Any Cause (Estimated up 24 Months) ]
- Pharmacokinetics (PK): Minimum Concentration (Cmin) of Ramucirumab [ Time Frame: Predose Day 1 Cycle 1 through Cycle 9 Day 1 (21 Day Cycles) ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
-
Metastatic disease or locally advanced, unresectable disease.
- Has histopathologically confirmed gastric or GEJ adenocarcinoma with documented disease progression after 0-2 prior lines of systemic therapy
- Has histopathologically confirmed nonsquamous or squamous NSCLC with documented disease progression after 0-3 prior lines of systemic therapy
- Has histopathologically confirmed transitional cell carcinoma of the urothelium (bladder, urethra, or renal pelvis) with documented disease progression after 1-3 prior lines of systemic therapy
- Has histologically confirmed biliary tract adenocarcinoma with documented progression after 1-2 prior lines of systemic therapy
- Availability of tumor tissue for biomarker analysis from a newly obtained core or excisional biopsy or willing to undergo a tumor biopsy. For first line NSCLC participants only, PD-L1 expression should be 1% or higher.
- Have an Eastern Cooperative Oncology Group Performance Status of 0 or 1.
- Has adequate organ function.
- Have an anticipated life expectancy of ≥3 months.
Exclusion Criteria:
- Have known brain metastases.
- Has received ≥3 lines of prior systemic therapy for gastric or GEJ adenocarcinoma and BTC or ≥4 lines for NSCLC or urothelial cancer.
- Has active autoimmune disease.
- Known human immunodeficiency virus (HIV) infection.
- Known active hepatitis B or hepatitis C infection.
- Has received any previous systemic therapy targeting vascular endothelial growth factor (VEGF) or VEGF receptor, or programmed death (PD) 1 or PD-ligand 1/2 signaling pathways.
- Have received a live vaccine within 30 days prior to enrollment. Seasonal flu vaccines that do not contain live virus are permitted.
- Have had a serious or non-healing wound, ulcer, or bone fracture within 28 days prior to enrollment.
- Have an elective or a planned major surgery during the course of the trial or has undergone major surgery within 28 days prior to enrollment.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02443324
United States, Connecticut | |
Yale University School of Medicine | |
New Haven, Connecticut, United States, 06520-8020 | |
United States, Florida | |
Florida Cancer Specialists | |
Fort Myers, Florida, United States, 33916 | |
Florida Cancer Specialists and Research Institute | |
Saint Petersburg, Florida, United States, 33705 | |
United States, Tennessee | |
Tennessee Oncology PLLC | |
Chattanooga, Tennessee, United States, 37404 | |
Sarah Cannon Research Institute SCRI | |
Nashville, Tennessee, United States, 37203 | |
Tennessee Oncology PLLC | |
Nashville, Tennessee, United States, 37203 | |
United States, Washington | |
Seattle Cancer Care Alliance | |
Seattle, Washington, United States, 98109 | |
France | |
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | |
Dijon Cedex, France, 21034 | |
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | |
Lille Cedex, France, 59020 | |
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | |
Lyon Cedex 08, France, 69373 | |
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | |
Paris CEDEX 05, France, 75248 | |
Germany | |
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | |
Dresden, Germany, 01307 | |
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | |
Heidelberg, Germany, 69126 | |
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | |
Tübingen, Germany, 72076 | |
Japan | |
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | |
Kochi-Shi, Japan, 780-0051 | |
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | |
Yamanashi, Japan, 400-0124 | |
Spain | |
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | |
Barcelona, Spain, 08035 | |
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | |
Madrid, Spain, 28050 | |
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | |
Pamplona, Spain, 31008 | |
United Kingdom | |
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | |
London, United Kingdom, W1G 6AD | |
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | |
Manchester, United Kingdom, M20 4BX | |
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | |
Sutton, United Kingdom, SM2 5PT |
Study Director: | Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) | Eli Lilly and Company |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Eli Lilly and Company |
ClinicalTrials.gov Identifier: | NCT02443324 |
Other Study ID Numbers: |
15787 I4T-MC-JVDF ( Other Identifier: Eli Lilly and Company ) 2015-001473-40 ( EudraCT Number ) KEYNOTE -098 ( Other Identifier: Merck ) |
First Posted: | May 13, 2015 Key Record Dates |
Last Update Posted: | August 18, 2022 |
Last Verified: | August 2022 |
immuno-oncology Vascular Endothelial Growth Factor (VEGF) angiogenesis PD-1 carcinoma of the bladder |
carcinoma of the urethra carcinoma of the ureter carcinoma of the renal pelvis carcinoma of the biliary tract |
Carcinoma Lung Neoplasms Carcinoma, Non-Small-Cell Lung Adenocarcinoma Biliary Tract Neoplasms Carcinoma, Transitional Cell Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms Respiratory Tract Neoplasms Thoracic Neoplasms Neoplasms by Site Lung Diseases Respiratory Tract Diseases Carcinoma, Bronchogenic |
Bronchial Neoplasms Digestive System Neoplasms Biliary Tract Diseases Digestive System Diseases Pembrolizumab Ramucirumab Antineoplastic Agents, Immunological Antineoplastic Agents Immune Checkpoint Inhibitors Molecular Mechanisms of Pharmacological Action Angiogenesis Inhibitors Angiogenesis Modulating Agents Growth Substances Physiological Effects of Drugs Growth Inhibitors |